Key takeaways
- GLP-1 users have reduced their consumption of frozen treats by at least 10%, according to Boston Consulting Group data.
What happened
A new report from the Boston Consulting Group (BCG) reveals that Americans using GLP-1 weight-loss medications have cut their consumption of frozen treats and ice cream by at least 10%. This shifts consumer demand away from traditional sugary desserts, prompting major food manufacturers to redesign their product lines with smaller portion sizes, cleaner ingredients, and higher protein content to accommodate the changing appetites of millions of patients.
Why it matters
The rapid adoption of GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound is fundamentally altering the multi-billion-dollar U.S. food industry. For patients obtaining weight-loss treatments through online GLP-1 providers, these dietary shifts represent a direct physiological change: the drugs mimic satiety hormones, significantly reducing cravings for high-fat and high-sugar foods. As a result, companies must adapt or risk losing a massive and highly lucrative segment of the consumer market.
For patients paying out-of-pocket for their weight-loss care, these shifting dietary habits also represent a minor offset in monthly expenses. While brand-name GLP-1s can cost upward of $1,000 per month without insurance, a 10% or greater reduction in household spending on processed snacks, ice cream, and fast food can help lower a patient’s overall monthly cost of living.
What the data says
According to data compiled by NielsenIQ, overall U.S. ice cream sales volumes fell by 1.5% year-on-year through June 13, 2026. However, the drop is significantly steeper among those taking weight-loss medications. Boston Consulting Group estimates that the roughly 16 million Americans currently taking GLP-1 medications have reduced their consumption of frozen treats by at least 10%.
To combat this drop-off, food manufacturers are heavily investing in wellness-oriented alternatives:
- The Magnum Ice Cream Company (which owns Magnum and Ben & Jerry’s) reports that its brands command a 26% share of the $2.2 billion U.S. "wellness and functional" ice cream segment.
- Yasso, a frozen Greek yogurt brand focused on portion control and protein, has experienced an average annual growth rate of approximately 20% over the last five years.
- Halo Top, a brand owned by Ferrero that markets lower-calorie ice cream, reports double-digit percentage sales growth over the past two years, compared to just 2.5% growth for the broader ice cream market, according to research firm Circana.
- Blue Bunny (also owned by Ferrero) reports surging demand for its 150-calorie "Mini Swirls" and is actively reformulating its recipes to completely eliminate high-fructose corn syrup and artificial colors and flavors.
How it compares
The shift in how ice cream manufacturers package and formulate their products closely mirrors broader trends across the entire food and beverage sector. Nutrition giant Nestlé and packaged food conglomerate Conagra have similarly restructured their product pipelines to emphasize protein, fiber, and smaller portion sizes.
For patients navigating their weight-loss journeys, these food industry changes make it easier to find compatible options in the grocery aisle. Traditional, high-sugar ice creams are increasingly being bypassed for "functional" alternatives that help patients meet their daily protein goals—a critical requirement for preserving lean muscle mass during rapid weight loss.
Understanding these nutritional requirements is a key part of choosing the right support structure for your weight-loss journey. When comparing options on our interactive provider map, patients often look for telehealth platforms that provide comprehensive nutritional counseling alongside medical prescriptions to ensure they maintain a balanced diet while eating less.
How this fits the bigger picture
The food industry's rapid pivot to accommodate GLP-1 patients highlights just how deeply these medications have penetrated American society. We previously reported on how one in five US adults have tried a GLP-1, illustrating a massive telehealth boom that has made these treatments accessible to millions. This widespread availability has forced consumer brands to rethink their long-term strategies.
Furthermore, the rise of GLP-1-driven wellness habits has created a secondary economic wave. As we detailed in our coverage of how Glanbia raised its profit forecast due to surging GLP-1 protein demand, the medical weight-loss boom has triggered unprecedented demand for whey protein and other nutritional supplements. Because GLP-1 users eat substantially smaller meals, they prioritize nutrient-dense, high-protein foods, driving up costs for protein manufacturers while traditional dessert companies scramble to catch up.
What happens next
With the number of GLP-1 users in the United States expected to climb significantly by the end of the decade, the pressure on food manufacturers will only intensify. Consumers can expect to see an accelerated rollout of "GLP-1 companion" food lines, smaller single-serve packaging, and cleaner ingredient profiles across grocery store shelves.
On the clinical and regulatory front, food companies will likely continue partnering with nutritional scientists to back their reformulated products with clinical claims. Meanwhile, telehealth providers are increasingly incorporating weight-loss companion apps and dietary tracking features into their monthly subscription costs, helping patients make healthier food choices as the retail landscape evolves.
Disclaimer: CompareRx does not provide medical advice. Always consult with a qualified healthcare professional before starting any weight-loss medication or making major changes to your diet.